Promise and Pitfalls of Proactive Gun Law Enforcement
October 19, 2017
January 17, 2018
Panels to cover the topics of FDA and open data, the value of transparency at FDA to investors, and how best FDA can correct misleading information in the marketplace. Featuring academic experts from Johns Hopkins, Harvard, Yale, and elsewhere. Introduction: Allan Coukell Senior Director for Health Programs The Pew Charitable Trusts Joshua M. Sharfstein, MD Professor of the Practice Department of Health Policy and Management Johns Hopkins Bloomberg School of Public Health Keynote: Scott Gottlieb, MD Commissioner of Food and Drugs US Food and Drug Administration Panel 1 Open Data: Kay Dickersin, PhD Professor, Epidemiology Johns Hopkins Bloomberg School of Public Health Sean Coady Statistician (Health) National Heart, Lung, and Blood Institute Matthew Herder, J.S.M., LL.M., LL.B. Director, Health Law Institute Associate Professor, Faculties of Medicine and Law Dalhousie University Joseph Solomon Ross, MD, MHS Associate Professor of Medicine and Public Health Yale University Interview: Jonathan Leff Partner, Deerfield Management Chairman, Deerfield Institute Joshua M. Sharfstein, MD Professor of the Practice Department of Health Policy and Management Johns Hopkins Bloomberg School of Public Health Panel 2 Correcting Misinformation: Peter Lurie, MD, MPH President, Center for Science in the Public Interest Erick H. Turner, MD Associate Prof., Dept. of Psychiatry, Oregon Health & Science University (OHSU) Associate Prof., Dept. of Pharmacology, OHSU Senior Scholar, Center for Ethics in Health Care, OHSU Staff Psychiatrist, VA Portland Health Care System Michael A. Carome, MD Director, Health Research Group Public Citizen Aaron S. Kesselheim, MD, JD, MPH Director, Program on Regulation, Therapeutics and Law Division of Pharmacoepidemiology and Pharmacoeconomics Brigham & Women's Hospital/Harvard Medical School Acknowledgement: Margaret E. McCarthy, PhD, MA, JD Executive Director, Yale Collaboration for Research Integrity and Transparency Yale University For more information, please contact the Office of Public Health Practice and Training at email@example.com or at (443)287-8541. This project is supported by a grant from the Laura and John Arnold Foundation. More information available here: www.jhsph.edu/fda-transparency.
January 8, 2018
The Johns Hopkins Center for Injury Research and Policy and the KTH Royal Institute of Technology in Stockholm, Sweden are convened a first-of-its-kind gathering to focus public attention on how to promote deployment of autonomous vehicle technology in ways that provide the greatest social benefits through a focus on safety and equity.
October 4, 2017
September 7, 2017
August 18, 2017
Public health is everywhere—from the water we drink, to the air we breathe. The Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, one of the largest in the country, is dedicated to advancing local, national and global health policy to make a difference. Within six degree programs (four masters’ and two doctoral), students have opportunities to engage directly with faculty, study internationally, and complete practicums in the field, contributing directly to global policy. Students will graduate with marketable skills and real-world experience, ready to make an impact, from the No. 1 school of public health.
May 25, 2017
HPM's Post-Election Policy Series May 9, 2017
May 23, 2017
May 23, 2017
Pop Up Practice Seminar at the Bloomberg School Recorded Wed, Feb 24 at Noon Moderator: Josh Sharfstein, MD, Associate Dean, Office of Public Health Practice and Training Panelists: Richard B. Brooks, MD, MPH, Epidemic Intelligence Officer, Maryland Department of Health and Mental Hygiene Carlos Castillo-Salgado, MD, DrPH, Professor of Epidemiology, Director of Global Public Health Observatory Elli Leontsini, MD, MPH, Assistant Scientist, Social and Behavioral Interventions Program, Department of International Health For more information, contact firstname.lastname@example.org or navigate to www.jhsph.edu/practice.
May 23, 2017
On October 29th, 2015, the Institute for Health and Social Policy convened leaders from across Maryland to discuss evidence-based approaches to addressing substance use disorders and drug-related violence in the state broadly and Baltimore City specifically. The full-day meeting brought together 75 high-level Maryland research, policy, and practice leaders from the law enforcement, substance use disorder treatment and policy, and violence prevention fields with the goal of developing policy recommendations that could be turned into legislation. The meeting began with expert presentations designed to summarize the evidence-base regarding substance use treatment and drug control policies.